Reply to: ‘‘Repeated transarterial chemoembolization: An overfitting effort?’’  by Adhoute, Xavier et al.
[6] Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox
regression model. Stat Med 1989;8:771–783.
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Letters to the EditorReply to: ‘‘Repeated transarterial chemoembolization:
An overﬁtting effort?’’
Retreatment with TACE: ABCR score and radiological response, a really tight connection
To the Editor,
We would like to thank Facciorusso et al. for their commentaries
on our article and for applying our ABCR score to their important
cohort of patients.
Transarterial chemoembolization (TACE) is recommended for
intermediate stage hepatocellular carcinoma (HCC) based on
the algorithm of the Barcelona–Clinic Liver Cancer (BCLC) system
[1,2], and is the most widely used treatment for HCC [3].
No consensus exists for treatment methods, number of
courses to be administered, objectives (complete or partial
response, disease stabilization), and retreatment schedule but
performing TACE guided by the radiologic response and individ-
ual tolerance appears to be the most logical option. Moreover, as
suggested by Bolondi et al., intermediate stage represents a
heterogeneous group of patients [4] and, in our group, as in some
other groups, a segmental portal vein thrombosis, corresponding
to BCLC C patients was not considered as an absolute contra-
indication for TACE. This can certainly impact on the efﬁcacy
and tolerance, and is therefore of crucial importance to know
relatively early, at least before severe toxicities, which patients
will beneﬁt from additional sessions.Table 1. Evolution of median overall survival following ABCR score with different thresholds in a merged cohort of 186 patients treated by TACE.
ABCR ABCR
[-3]
(n = 20)
ABCR
[-2]
(n = 3)
ABCR
[-1]
(n = 52)
ABCR
[0]
(n = 31)
ABCR
[1]
(n = 5)
ABCR
[2]
(n = 34)
ABCR
[3]
(n = 24)
ABCR
[4]
(n = 13)
ABCR 
[5]
(n = 1)
ABCR
[6]
(n = 3)
Median survival 
months [95% CI]
38
[31-72]
31
[26-36]
38
[24-50]
25
[20-27]
24
[3-24]
18
[15-20]
13
[12-15]
7
[6-9]
8
[n.a.]
5
[4-11]
p value <0.0001
Median survival 
months [95% CI]
31 [25-38] 15 [14-19] 7 [6-9]
p value <0.0001
Median survival 
months [95% CI]
37 [31-46] 17 [14-19]
p value <0.0001
Median survival 
months [95% CI]
31 [25-38] 14 [12-17]
p value <0.0001
Median survival 
months [95% CI]
31 [25-38] 14 [12-17]
p value <0.0001
Median survival 
months [95% CI]
26 [24-31] 11 [8-13]
p value <0.0001
Median survival 
months [95% CI]
25 [21-27] 7 [6-9]
p value <0.0001
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patients in order to know if it is possible to extend indication of
TACE towards some more advanced HCC cases.
Conﬂict of interest
Adhoute Xavier: Board member (Bayer). Penaranda Guillaume:
grant from Bayer. Raoul Jean-Luc: Board member (Bayer, BMS,
Daichi). Bourliere Marc: Board member (Merck-Schering
Plough, Giléad, Janssen, Vertex, Boehringer-Ingelheim, BMS,
Roche, Abbvie, GSK), speaker (Merck-Schering Plough – Giléad,
Janssen, Vertex, Boehringer-Ingelheim, BMS, Roche, Abbvie,
Novartis, GSK).
Authors’ contributions
XA, MB, JLR are MD in charge of the patients; XA, MB collected
the data and GP proceed to statistical analysis; XA, GP wrote
the letter; JLR and MB revised the manuscript.
References
[1] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet
2012;379:1245–1255.
[2] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable
hepatocellular carcinoma: Chemoembolization improves survival.
Hepatology 2003;37:429–442, Review.
[3] Park JW, Sherman M, Colombo M, Roberts LR, Schwartz M, Degos F, et al.
Observations of hepatocellular carcinoma (HCC) management patterns from
the global HCC bridge study: ﬁrst characterization of the full study
population. J Clin Oncol 2012;30:Abstr 4033. Abstract.
[4] Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al.
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular
Carcinoma: proposal for a subclassiﬁcation to facilitate treatment decisions.
Semin Liver Dis 2012;32:348–359.
[5] Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs
AK, et al. EASL and mRECIST responses are independent prognostic factors for
survival in hepatocellular cancer patients treated with transarterial emboliza-
tion. J Hepatol 2011;55:1309–1316.
[6] Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al.
Evolving strategies for the management of intermediate-stage hepatocellular
carcinoma: available evidence and expert opinion on the use of transarterial
chemoembolization. Cancer Treat Rev 2011;37:212–220.
[7] Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, et al. Clinical decision
making and research in hepatocellular carcinoma: pivotal role of imaging
techniques. Hepatology 2011;54:2238–2244.
Xavier Adhoute⇑
Department of Hepato-Gastroenterology,
Hôpital Saint-Joseph Marseille, France⇑Corresponding author.
E-mail address: adhoute.xavier@neuf.fr
Guillaume Penaranda
AlphaBioLaboratory, Marseille, France
Jean Luc Raoul
Department of Hepato-Gastroenterology
and Digestive Oncology,
Institut Paoli Calmette Marseille, France
Marc Bourlière
Department of Hepato-Gastroenterology,
Hôpital Saint-Joseph Marseille, France
JOURNAL OF HEPATOLOGY
ABCR score can be used as an aid to the decision making pro-
cess before retreatment with the second and/or the third TACE,
but it must be validated in a prospective study. It consists of
parameters already used by clinicians to guide their decision,
including a worsening of liver function after TACE and radiologi-
cal response (by EASL criteria) [5], which is assigned with the
highest coefﬁcient (3 points), whether partial or complete.
In our HCC cohorts, representative of common practice includ-
ing mostly BCLC B HCC and BCLC A HCC that are not suitable for
curative treatment and less frequently stage C HCC due to seg-
mental portal vein thrombosis (less than 10% in our validation
cohorts), the calculated score before the second TACE is clearly
correlated with the overall survival (OS). In our experience, we
distinguished three groups with signiﬁcantly different survival.
One can suppose that the cut-off values described in our paper
can differ from one team to another depending on inclusion cri-
teria. In our experience, patients with ABCR score P4 do not
beneﬁt from an additional course. The Milan team found close
results (median OS of ABCR 60 and [1–3] groups, 39 and
40 months respectively vs. ABCR P4, 13 months). The non-
signiﬁcance (p = 0.19) is probably related to the low number of
patients in the ABCR P4 group (n = 7). It would be of interest
to know if in their experience, of clearly excellent candidates
for TACE, there exist also a linear relationship between score
and OS.
Since the publication, we tested the ABCR score in a merged
cohort of 186 patients, median age 69 [66–70] years, with BCLC
A HCC 17%, BCLC B HCC 66% and BCLC C HCC 17%, Child-Pugh A
cirrhosis 86%, mostly related to alcohol (42%) and viral disease
(32%). Consistently, we found a correlation between score and
survival (Table 1). Logistic regression analysis on each score
threshold shows that several thresholds are possible, but the
threshold P3 seems the best compromise (AUC [CI 95%] 0.785
[0.728; 0.844], likelihood ratio (LR) 33.04, p <0.0001, Akaike
information criterion (AIC) 167.175) relative to a value threshold
P2 (AUC [CI 95%] 0.715 [0.657; 0.769], (LR) 32.03, p <0.0001, AIC
222. 808).
The difference between the ABCR 60 and ABCR [1–3] groups
mainly involves the presence of a radiological response
(3 points); for example 94% of patients in the group ABCR 60
against 2% for the ABCR group [1–3] had a radiological response
in this new analysis. The Milan team did not ﬁnd any difference
in survival between the two groups in their cohort, likely because
a radiological response was observed later, after the second TACE
in the ABCR [1–3] group. The optimal time point for assessment
to TACE response is not speciﬁed, several algorithms have been
proposed [6,7]. Taking into account the fact that some of our
patients were not considered in the BCLC guidelines as good can-
didates for TACE, we considered that an early evaluation will be
crucial in order to stop an early detrimental effect.
We share the comment about the possible over-ﬁtting and
that is why sharing experience from other groups is of major
interest and we thank the Milan team for their help.
Experiences utilizing our ABCR score in other institutes would
be interesting and most welcome.
The bootstrap sampling as proposed by Facciorusso et al.
seems to be attractive and needs to be applied in new cohorts.
Finally, we fully agree with this letter to the Editor that it is of
paramount importance now to improve prognostication and indi-
cation to retreatment, but perhaps in a more extended cohort ofJournal of Hepatology 2015 vol. 62 j 1438–1454 1443
